OneMain Financial (OMF) Prices 8M Share Secondary Offering at $53.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pre-Open Stock Movers 04/29: (VER) (OSTK) (FB) Higher; (ADVM) (CTXS) (EBAY) Lower (more...)
April 29, 2021 9:20 AM EDTToday's Pre-Open Stock Movers:
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) 54% LOWER; announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.
Galera Therapeutics, Inc. (Nasdaq:... More
After-Hours Stock Movers 04/28: (GRTX) (AZPN) (CAKE) Higher; (ADVM) (CMCO) (HOLX) Lower (more...)
April 28, 2021 5:45 PM EDTToday's After-Hours Movers:
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) 54% LOWER; announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.
Galera Therapeutics, Inc. (Nasdaq:... More
OneMain Financial (OMF) Announces Proposed 8M Share Secondary Offering of Common Stock
April 28, 2021 5:13 PM EDTOneMain Holdings, Inc. (NYSE: OMF) (the Company) announced today the commencement of a proposed secondary public offering of 8,000,000 shares of the Companys common stock by certain entities managed by affiliates of Apollo Global Management, Inc. and Värde Partners, Inc. (together, the selling stockholders). The 8,000,000 shares of... More
OneMain (OMF) PT Raised to $72 at Credit Suisse
April 28, 2021 6:05 AM EDTCredit Suisse analyst Moshe Orenbuch raised the price target on OneMain (NYSE: OMF) to $72.00 (from $69.00) while maintaining a Outperform rating.... More
OneMain (OMF) PT Raised to $72 at Barclays
April 28, 2021 5:38 AM EDTBarclays analyst Mark DeVries raised the price target on OneMain (NYSE: OMF) to $72.00 (from $69.00) while maintaining a Overweight rating.... More
